Atazanavir/cobicistat
Подписчиков: 0, рейтинг: 0
| Combination of | |
|---|---|
| Atazanavir | HIV protease inhibitor |
| Cobicistat | Cytochrome P450 (CYP3A) inhibitor |
| Clinical data | |
| Trade names | Evotaz |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Atazanavir/cobicistat, sold under the brand name Evotaz, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains atazanavir and cobicistat. Atazanavir is an HIV protease inhibitor and cobicistat is an inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A family.
Atazanavir/cobicistat was approved by the Food and Drug Administration (FDA) for medical use in United States in January 2015. It was approved for medical use in the European Union in July 2015.
Medical uses
Atazanavir/cobicistat is indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1 infection in people weighing at least 35 kilograms (77 lb).
External links
- "Atazanavir mixture with cobicistat". Drug Information Portal. U.S. National Library of Medicine.